|
The data published on
Disclosure UK today shows that the industry invested
£381.2 million on R&D activities in the UK during
2019, up from £377.3million in
2018.
Disclosure UK is the public,
pharmaceutical industry-led database which details
aggregate R&D spend, as well as individual payments
and benefits in kind made to UK healthcare professionals
(HCPs) and healthcare organisations
(HCOs).
Last month the ABPI announced it
would be publishing 2019 data in a way which minimises
any pressure on NHS workers, hospitals and other NHS
organisations as they respond to the COVID-19
pandemic.
This means that some of the 2019
data is not broken down by individual HCPs and HCOs as
usual. This was a temporary change because of the
pandemic, and the ABPI plans to republish the usual, more
detailed data as soon as
possible.
The available 2019 figures
show:
- £538.2million has been
disclosed by pharmaceutical companies for 2019, compared
with £503million in 2018 (excluding
joint-working*).
- £381.2million of this was spent
on R&D, compared with £377.3million in
2018.
- £157million of this was spent
on non-R&D collaborations with HCPs and HCOs in 2019,
vs £125.7million in 2018 (excluding joint-working*). Much
of this increase was due to payments to healthcare
organisations.
11 new companies have disclosed
payments this year, bringing the total number of
companies using Disclosure UK to
143.
Richard Torbett,
Chief Executive of the ABPI,
said:
“The 2019 disclosure data
available so far tells a hugely positive story – the
third successive year of increasing investment by
industry in UK R&D. This can only be a good thing for
patients and the
NHS.
“We will publish the normal
breakdown of disclosure data as soon as we are able, and
when we do, it should also help us understand more about
how the data has changed over
time.
“We’re proud of the work we
do with the NHS, without which the development of new
medicines and vaccines would be impossible, and will
continue strive for the highest levels of openness and
transparency in the relationships between industry and
healthcare
professionals.”
ABPI Code
consultation
As part of the work to evolve
disclosure under the ABPI Code of Practice for the
pharmaceutical industry, the ABPI is consulting on the
proposed 2021 Code.
It includes a proposal for an
additional requirement to disclose payments for
contracted services paid to members of the public (not
representing a patient organisation) to include patients
and journalists, from 2022. (to be disclosed in
2023).
People can respond to the
consultation here and there is more information
on the PMCPA
website.
#ENDS#
|
